Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL4381079 | 0.98 | TSHR (0.35) | TSHRNAPRTTDP1CYP11B2 | |
| Pyridine SCHEMBL28304390 | 0.98 | TSHR (0.35) | TSHRNAPRTTDP1CYP11B2 | |
| Pyridine SCHEMBL29359954 | 0.91 | TSHR (0.30) | TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL30530223 | 0.91 | TSHR (0.30) | TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL27607142 | 0.82 | TSHR (0.35) | TSHRNAPRTTDP1CYP11B2 | |
| SCHEMBL10803233 | 0.80 | — | — | |
| Benzene SCHEMBL9464137 | 0.78 | KDM4E (0.30) | — | |
| Pyridine SCHEMBL10582176 | 0.76 | TSHR (0.36) | TSHRNAPRTTDP1CYP11B2 | |
| Pyridine SCHEMBL9510891 | 0.75 | TSHR (0.64) | TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL6100271 | 0.74 | SMN1; SMN2 (0.33) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352324-B2 | Methods | MEDIMMUNE LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3759071-A1 | METHODS | MedImmune Limited (GB) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399215-A1 | METHODS | MEDIMMUNE LIMITED (GB) | 2020-12-24 | — | — | US | disclosed |
| CN-111801316-A | Method of producing a composite material | 免疫医疗有限公司 | 2020-10-20 | — | — | CN | disclosed |
| EP-3292101-A1 | TRICYCLIC SULFONES AS ROR MODULATORS | Bristol-Myers Squibb Company (US) | 2018-03-14 | — | — | EP | disclosed |
| CN-107709295-A | Tricyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2018-02-16 | — | — | CN | disclosed |
| WO-2016179460-A1 | TRICYCLIC SULFONES AS RORϒ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352324-B2 | Methods | SIN3A, RCC2, RPS3 | TSHR 1078/4885NAPRT 4428/4885TDP1 3652/4885 |
| US-20200399215-A1 | METHODS | SIN3A, RCC2, RPS3 | TSHR 1078/4885NAPRT 4428/4885TDP1 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.